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imonabant: A Cannabinoid Receptor Type 1 Blocker for
anagement of Multiple Cardiometabolic Risk Factors
li V. Gelfand, MD,* Christopher P. Cannon, MD†
oston, Massachusetts
Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being
developed for the treatment of multiple cardiometabolic risk factors, including abdominal
obesity and smoking. In four large trials, after one year of treatment, rimonabant 20 mg led
to greater weight loss and reduction in waist circumference compared with placebo. Therapy
with rimonabant is also associated with favorable changes in serum lipid levels and an
improvement in glycemic control in prediabetes patients and in type 2 diabetic patients. At
the same dose, rimonabant significantly increased cigarette smoking quit rates as compared
with placebo. Rimonabant seems to be well tolerated, with a primary side effect of mild
nausea. As an agent with a novel mechanism of action, rimonabant has a potential to be a
useful adjunct to lifestyle and behavior modification in treatment of multiple cardiometabolic
risk factors, including abdominal obesity and smoking. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.0671919–26) © 2006 by the American College of Cardiology Foundation
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cBESITY, METABOLIC SYNDROME,
ND SMOKING: THE SCOPE OF THE PROBLEM
ardiovascular disease remains by far the leading cause of
orbidity and mortality in the developed world, accounting
or almost one million deaths annually in the U.S. alone.
obacco smoking remains the primary preventable cause of
eath, contributing to nearly 20% of all deaths worldwide.
ecent startling reports project a decline in life expectancy
n the U.S. during the 21st century (1). These reports warn
f a catastrophic impact of the global obesity epidemic on
ates of diabetes mellitus and cardiovascular disease in the
pcoming years. Currently in the U.S., 28% of men and
4% of women are obese, and the largest increases in obesity
ates have affected children and minorities (2). In this
ountry, obesity is estimated to be associated with over
00,000 excess deaths every year (3).
The old view of adipose tissue as an inert storage depot
as supplanted more recently by its depiction as a dynamic
ndocrine organ. Adipose tissue secretes a variety of factors,
r adipokines, that contribute to insulin resistance, vascular
ndothelial dysfunction, and atherogenesis (4,5). It is there-
ore not surprising that abdominal obesity is not an isolated
athophysiological entity, but often coexists with hyperten-
ion, glucose intolerance, and dyslipidemia. Recognizing
his, the 2001 National Cholesterol Education Program
From the *Cardiovascular Division, Department of Medicine, Beth Israel Deacon-
ss Medical Center, and the †TIMI Study Group, Cardiovascular Division, Depart-
ent of Medicine, Brigham and Women’s Hospital, Harvard Medical School,
oston, Massachusetts. Dr. Cannon serves on advisory boards and consult for
anofi-Aventis and has spoken at medical symposia sponsored by this company. The
uthors also recently completed a trial (CLARITY-TIMI 28) sponsored by Sanofi-
ventis, but do not currently have ongoing research grants. Dr. Cannon serves as an
npaid member of the STRADIVARIUS trial Steering Committee, led by Dr.f
teven E. Nissen.
Manuscript received November 29, 2005, accepted December 14, 2005.Adult Treatment Panel III) put forward specific guidelines
hat define a population with metabolic syndrome (Table 1)
6), and describe individuals with a markedly elevated risk of
eveloping diabetes and clinically significant atherosclerosis.
ndeed, the presence of metabolic syndrome may be asso-
iated with a significant excess burden of myocardial infarc-
ion, stroke, and overall cardiovascular mortality (7).
Modification of cardiometabolic risk factors, including
moking and abdominal obesity, has a well-documented
avorable effect on clinical outcomes. Smoking cessation is
ssociated with a rapid decrease in the risk of developing
dverse cardiovascular events, including myocardial infarc-
ion, stroke, and sudden death (8,9). A decrease in body
eight and reduction in waist circumference is associated
ith favorable changes in the lipid profile and C-reactive
rotein and a decrease in mortality (10,11). However,
uccess with behavior modification and currently available
edications in achieving reliable abstinence from tobacco
nd with sustained weight loss is quite limited. Surgical
rocedures, such as gastric banding or gastric bypass, are
ffective for sustained weight loss, but are clearly invasive and
re associated with nontrivial morbidity and mortality (12).
herefore, these are generally used as a last resort for patients
ith morbid obesity (body mass index [BMI]40 kg/m2) and
hose with multiple obesity-related complications (13). With
egard to smoking cessation, behavioral therapy, nicotine
eplacement therapy, and pharmacologic approaches (bupro-
rion) have generally yielded only modest quit rates (14), and
any individuals resume smoking within one year. Addition-
lly, many who successfully quit smoking gain a considerable
mount of weight, which serves as a barrier for those who are
onsidering tobacco cessation.
Despite disappointing results for treatment of obesity and
or smoking cessation, both are mandated as part of the
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Rimonabant May 16, 2006:1919–26verall cardiometabolic risk factor reduction for primary and
econdary prevention of heart disease (Table 2) (15,16). An
ntriguing new combined approach to treating the obesity
nd glucose intolerance features of metabolic syndrome, as
ell as aiding smoking cessation, involves manipulation of
he endogenous cannabinoid system, specifically with the
annabinoid receptor type 1 (CB1) antagonist rimonabant.
HE ENDOCANNABINOID SYSTEM
annabis. Hemp (Cannabis sativa) has been cultivated in
any parts of the world for over 4,500 years. The plant is
sed for its fiber and oil, and abused as a recreational drug
marijuana, hashish). The main psychoactive alkaloid in
annabis is -9-tetrahydrocannabinol (THC), but the plant
ontains more than 60 other cannabinoids, some of which
odulate the actions of THC. Synthetic THC (dronabinol)
s used to treat post-chemotherapy nausea and emesis, as
ell as anorexia associated with human immunodeficiency
irus infection.
annabinoid receptors and their ligands. The cannabi-
oids exert their pharmacologic action through the interac-
ion with the specific receptors CB1 and CB2, which were
escribed in the late 1980s and later were cloned (17,18)
Table 3). The CB1 receptors are primarily distributed to
he brain (19) and adipose tissue (20), but are also found in
he myocardium (21), vascular endothelium (22), and sym-
athetic nerve terminals (23). The CB2 receptors are pri-
arily located in the lymphoid tissue and peripheral mac-
ophages (24). Both receptors function as transmembrane
-proteins. Existence of CB3 receptors has been postulated
25), but the receptor itself has not yet been cloned.
Cannabinoid receptors have affinity for at least two
ndogenous ligands: small lipid molecules arachidonyleth-
able 1. Components of Metabolic Syndrome, as Defined
y the Adult Treatment Panel III
t least three of the following traits
Abdominal obesity
Men, 102 cm (40 inches)
Women, 88 cm (35 inches)
Serum triglycerides 150 mg/dl (1.7 mmol/l)
Serum high-density lipoprotein cholesterol 40 mg/dl (1 mmol/l)
in men and 50 mg/dl (1.3 mmol/l) in women
Blood pressure 130/85 mm Hg
Fasting plasma glucose 110 mg/dl (6.1 mmol/l)
Abbreviations and Acronyms
BMI  body mass index
CB1  cannabinoid receptor type 1
HDL  high-density lipoprotein
LDL  low-density lipoprotein
RIO  Rimonabant in Obesity
STRATUS  Studies with Rimonabant
and Tobacco Use
THC  tetrahydrocannabinoldapted with permission (6).
N
Rnolamide (anandamide), and 2-arachidonoylglycerol (2-
G). Under normal conditions, the endocannabinoid sys-
em is not tonically active, rather endocannabinoids are
roduced on demand, act locally, and are rapidly inactivated
ia cellular uptake and enzymatic hydrolysis (26).
More recently, cannabinoid antagonists were developed,
f which rimonabant has been the most extensively studied.
t has a high affinity for the central CB1 receptors (27), and
ts potential clinical uses will be discussed later in this
eview.
HYSIOLOGY OF THE CANNABINOID SYSTEM
ardiovascular effects. Cannabinoids have long been
nown to have potent psychotropic actions, but their wide-
anging effects on the cardiovascular system are just begin-
ing to be unraveled.
In anesthetized rat models, intravenously administered
nandamide produces a triphasic hemodynamic response
28): a brief period of vagally mediated bradycardia and
ypotension, followed by a transitory pressor reaction, and a
elatively prolonged vasodepressor response. The latter is
he dominant effect of anandamide in animal models, and it
able 2. ACC/AHA Unstable Angina and Non–ST-Segment
levation Myocardial Infarction Guidelines: Risk Factor
odification
moking cessation*
chievement of optimal body weight*
aily exercise
HA diet
ontrol of hypertension to BP 130/85 mm Hg
ight control of hyperglycemia in diabetic patients*
ipid-lowering agents for LDL 130 mg/dl
ipid-lowering agent in LDL 100 mg/dl after diet
rug therapy if HDL 40 mg/dl*
Can be impacted by rimonabant. Data from Braunwald et al. (16).
ACC  American College of Cardiology; AHA  American Heart Associ-
tion; BP  blood pressure; HDL  high-density lipoprotein; LDL  low-density
ipoprotein.
able 3. History of Endocannabinoid System Research
nd Rimonabant Trials
964 Isolation of -9 THC, the active constituent of Cannabis
sativa
988 High-affinity cannabinoid binding site discovered in rat brain
990 Cloning of the rat G-protein–coupled CB1 receptor
991 Cloning of the human CB1 receptor
992 Discovery of anandamide, the first endogenous cannabinoid
993 Cloning of the peripheral CB2 receptor
994 Characterization of the first selective CB1 receptor blocker,
rimonabant
995 Isolation of a second cannabinoid, 2-AG, in brain
004 RIO-Lipids, RIO-Europe 1 year, STRATUS-US, and RIO-
NA studies presented
005 RIO-Europe and RIO-Lipids published
RIO-Diabetes study presented
006 RIO-NA study published
dapted with permission from a presentation by Dr. J. P. Despres (Quebec Heart
nstitute, Ste. Foy, Quebec, Canada), and updated.
2-AG  2-arachidonoylglycerol; CB1  cannabinoid receptor type 1; NA 
orth America; RIO  Rimonabant in Obesity; STRATUS  Studies with
imonabant and Tobacco Use; THC  tetrahydrocannabinol; US  United States.
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May 16, 2006:1919–26 Rimonabantesults from CB1-mediated inhibition of norepinephrine
elease from presynaptic nerve terminals (29). In humans,
cute administration of the cannabinoids produces vasodi-
ation and tachycardia with a variable net effect on systemic
lood pressure (30), but long-term use of THC results in
B1-mediated hypotension and bradycardia (31,32).
Although CB1 receptors are mostly expressed on the
euronal terminals, there is evidence showing that other cell
ypes express these receptors and participate in cannabinoid
hysiology. Endocannabinoids induce vasodilation by acting
irectly on the CB1 receptors in the arterial smooth muscle
n the brain (33). These compounds also induce vasodilation
n a variety of vascular beds through an endothelium-
ependent increase in nitric oxide synthesis (34), but at least
ome of the vasodilation is probably independent of the CB1
eceptor system.
Endocannabinoid systems seem to be involved in regula-
ion of vascular tone in hepatic disease, hypertension, and
ther disorders. In advanced cirrhosis, endocannabinoids
ediate the vasodilatory state through their interaction with
he CB1 receptors. In spontaneously hypertensive rats, the
ardiac and vascular endothelial CB1 system becomes ton-
cally active, and such animals show a more pronounced
asodepressor/hypotensive response to anandamide than do
ild types (35). Rimonabant blocks the vasodepressor effect
f anandamide in hypertensive animals, but not in normal
nimals, indicating that the CB1 system is largely inactive
nder normal hemodynamic conditions.
Recent work shows that the endocannabinoid system also
lays a role in hemodynamics of shock states. Indeed, under
onditions of experimental hemorrhage (36), myocardial
nfarction (37), or endotoxemia (38,39), macrophages and
irculating platelets elaborate anandamide, which contrib-
tes to the onset of hypotension and shock. Blockade of
B1 receptors with rimonabant attenuates these effects.
etabolic effects. There is increasing evidence showing
hat the endocannabinoid system plays a central role in
egulating metabolism and body composition by enhancing
he central orexigenic drive and increasing peripheral lipo-
enesis (Table 4) (40).
Control of food intake and body composition is the result
f a series of complex interactions between the adipocytes,
he mesolimbic system, the hypothalamus, and the gastro-
ntestinal tract. A sense of hunger is mediated in part by the
ut hormone ghrelin, which is produced in higher concen-
able 4. The Effects of CB1 Blockade on Food Intake and
ardiometabolic Risk Factors
entral blockade
(hypothalamus)
Decreased food intake
eripheral blockade
(adipose tissue)
Decreased abdominal fat (waist circumference)
1 Adiponectin
2 Triglycerides
1 High-density lipoprotein
2 Small, dense low-density lipoprotein
2 C-reactive proteint2 Insulin resistancerations during diet-induced weight loss (41). Leptin, an
ndogenous hormone, can reduce the food intake. Serum
oncentration of leptin is directly proportional to the degree
f adiposity, but obese individuals have lower sensitivity to
eptin (42). An adipose tissue-specific protein, adiponectin,
timulates fatty acid oxidation and a decrease in body
eight. Its levels are reduced in obesity (43).
Both cannabinoid receptors and their endocannabinoid
igands are present in all of the tissues that play an important
ole in regulation of food intake. Levels of endocannabi-
oids in the hypothalamus are decreased after administra-
ion of leptin (44). The CB1 agonists are potent, dose-
ependent inducers of hyperphagia in rodents (45–47), and
ntagonism of CB1 receptors prevents hyperphagia in a
tarvation model (44). Knockout mice lacking CB1 recep-
ors show a lean phenotype, primarily as a result of spon-
aneously reduced caloric intake (40). Indeed, when such
nimals are fed a high-fat, obesity-promoting diet, they
emain lean, and compared with wild-type animals, show
ower plasma insulin levels and a higher sensitivity to leptin
48). In the liver, endocannabinoids, acting via CB1 recep-
ors, act to induce lipogenic gene expression and stimulate
e novo synthesis of fatty acids (49).
ndocannabinoids and addiction. Regions of the brain
hought to be involved in drug relapse behavior contain high
evels of CB1 receptors (19), and compelling evidence
uggests a role for the endocannabinoid system in formula-
ion and propagation of addiction to psychoactive sub-
tances. Specifically, endocannabinoids seem to modulate
ue reactivity and conditioned reinforcement after pro-
onged abstinence of drug and natural reinforcers (50).
hese effects have been shown for a wide range of addictive
ubstances, including cocaine (51), heroin (52), amphet-
mines (53), and alcohol (54). Studies have shown an
mportant role for the endocannabinoid system in the
odulation of nicotine addiction. Indeed, the rewarding
ffects of nicotine were abolished in knockout mice lacking
B1 receptors (55), and as described further below, admin-
stration of the selective CB1 antagonist rimonabant de-
reases nicotine-seeking behaviors (56). Interestingly, endo-
annabinoid involvement in nicotine dependence seems to
e limited to its psychological aspects, as the physical
spects of nicotine withdrawal are not attenuated in CB1-
eficient mice (57).
IMONABANT
imonabant was first described in 1994 by Rinaldi-
armona et al. (27). At lower concentrations, it blocks the
B1 receptors. At very high concentrations, rimonabant
ehaves as a CB2 receptor antagonist (27), blocks calcium
nd potassium channels (58), and may directly affect cellular
ap junctions (59).
imonabant for treatment of obesity and cardiometa-
olic risk factors: animal data. The impact of rimonabant
herapy on metabolism, food intake, and body composition
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Rimonabant May 16, 2006:1919–26as first investigated by several groups in standard rodent
odels. In an important study, Di Marzo et al. (44) showed
hat treatment with rimonabant was associated with a
eduction in food intake and a 4% loss of body weight in
ild-type mice, but not in CB1 receptor-deficient mice.
ecrease in adiposity accounted for most of the
imonabant-induced weight loss, because muscle mass re-
ained unchanged (60). Ravinet-Trillou et al. (61) showed
hat in mice with diet-induced obesity, rimonabant therapy
as associated with only a transient reduction in food
ntake, but a marked and sustained weight reduction (20%)
nd a depletion of fat stores (50%). In that study,
imonabant-treated animals showed lower plasma glucose
nd insulin levels, as well as improved insulin resistance.
otable recent findings by the same group suggest that
ecreased food intake alone cannot account for the sus-
ained weight loss during rimonabant treatment. In fact,
fter the first week of treatment, a mild increase in food
ntake ensues, yet steady weight loss continues (60). Expla-
ation may lie with the evidence that rimonabant induces
hanges in the adipose tissue both at the cellular and at the
olecular levels. Grossly, adipocytes in rimonabant-treated
nimals are smaller and reflect a marked decrease in fat
tores rather than adipocyte apoptosis (60). Using deoxyri-
onucleic acid chip technology, Jbilo et al. (60) showed that
ene modulations induced by rimonabant treatment were
pposite to those effected by a high-fat diet, and were very
imilar to those in CB1 knockout mice. Rimonabant was
lso shown to increase adiponectin levels by stimulating
diponectin messenger ribonucleic acid expression in the
dipocytes (20). These findings lend strong support to the
B1-mediated mechanism of the anti-obesity action of
imonabant. In addition, treatment with rimonabant was
ssociated with an induction of several glycolytic enzymes,
hich could explain the glucose-lowering effect of rimon-
bant. Finally, there was a reduction in the expression of
ultiple pro-inflammatory proteins, known to be upregu-
ated in obesity (60).
able 5. Clinical Trials of Rimonabant (as of December 2005)
Name (Ref. No.) Status n Sponsor
IO-Lipids (62) Published 1,036 Sanofi-Aventis
IO-Europe (64) Published 1,507 Sanofi-Aventis
IO-NA (65) Published 3,040 Sanofi-Aventis
IO-Diabetes (66) Presented 1,045 Sanofi-Aventis
TRATUS-US (68) Presented 787 Sanofi-Aventis
TRATUS-EU Completed 787 Sanofi-Aventis
TRATUS-WW Presented 5,055 Sanofi-Aventis
TRADIVARIUS (67) Enrolling 800 (projected) Sanofi-Aventis
imonabant to
Reduce Alcohol
Consumption (69)
Enrolling 40 (projected) National Institutes
of Health
U  Europe; NA  North America; RIO  Rimonabant in Obesity;
TRADIVARIUS  Strategy to Reduce Atherosclerosis Development Involvingi
dministration of Rimonabant—The Intravascular Ultrasound Study; STRATUS 
tudies with Rimonabant and Tobacco Use; US United States; WW worldwide.imonabant for treatment of obesity: trials in humans.
ased on the animal data, the Rimonabant in Obesity
RIO) phase 3 program of four randomized double-blind
lacebo-controlled clinical trials in humans was initiated
Table 5).
HE RIO-LIPIDS TRIAL. The RIO-Lipids trial enrolled
,036 patients with mild or moderate obesity (mean BMI,
4 kg/m2) and untreated hyperlipidemia (62). Patients were
andomized in a parallel fashion to receive rimonabant 20
g/day, rimonabant 5 mg/day, or matching placebo for one
ear, and weight loss was assessed at the end of treatment.
t the end of one year, treatment with rimonabant was
ssociated with significantly greater weight loss compared
ith placebo (Fig. 1). Indeed, 58.4% of subjects in the
igh-dose rimonabant group had sustained a loss of 5%
ody weight, compared with 30.0% in the low-dose rimon-
bant group and 19.5% in the placebo group (p  0.001 for
igh-dose rimonabant vs. placebo). A more substantial
10% weight loss was sustained by 32.6% of subjects in the
igh-dose rimonabant group, compared with 10.6% in the
ow-dose group and 7.2% in the placebo group (p  0.001
or high-dose rimonabant vs. placebo) (Fig. 2). Among
atients who completed a full one-year course of treatment,
2.9% of patients in the high-dose group lost 5% body
eight, compared with 27.6% for placebo (p  0.001).
ith regard to the lipid parameters, at the end of treatment
he subjects in the high-dose rimonabant group had a 23%
ncrease in high-density lipoprotein (HDL) levels and a
5% decrease in triglyceride levels. Both were different from
lacebo (p  0.001 for both). The C-reactive protein levels
ere lower in the high-dose rimonabant group (27% reduc-
ion vs. 11% for placebo, p  0.007), and the low-density
ipoprotein (LDL) levels were not significantly affected by
reatment. Rimonabant 20 mg also increased adiponectin
evels by 57.7% (p  0.001), a change that was partly
igure 1. Change in body weight among subjects in the Rimonabant in
besity (RIO)-Lipids study. Reprinted, with permission, from Despres et
l. (62).ndependent of weight loss alone. An important final
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May 16, 2006:1919–26 Rimonabantnding was that at the end of treatment, the proportion of
atients satisfying the National Cholesterol Education
rogram-Adult Treatment Panel III criteria for metabolic
yndrome was significantly lower in the high-dose rimonabant-
reated group compared with placebo (25.8% vs. 41.0%, p
.001) (62).
HE RIO-EUROPE TRIAL. Results of RIO-Lipids were con-
rmed in a similar-sized RIO-Europe trial (63,64) that
nrolled obese subjects with BMI 30 kg/m2, or 27
g/m2 with a comorbidity, defined as hypertension or
yslipidemia. In this trial, 1,507 subjects were enrolled and
ssigned randomly to receive rimonabant 20 mg/day,
imonabant 5 mg/day, or placebo. Subjects were also given
nstructions for moderate physical exercise and a mild
ypocaloric diet. Among patients completing one full year
f treatment (61%), loss of 5% body weight was achieved
ignificantly more frequently in both rimonabant groups
ompared with placebo (67.4% for 20 mg, 44.2% for 5 mg
s. 30.5% for placebo, p  0.01 for both placebo compar-
sons). Treatment with either dose of rimonabant was also
ssociated with significantly greater waist circumference
eduction than placebo (6.5 cm for 20 mg, 3.9 cm for 5 mg,
.4 cm for placebo, p  0.01 for both comparisons).
riglyceride levels decreased and HDL levels increased in
oth rimonabant groups, and the investigators suggested
hat elevated levels of adiponectin were contributing to
hese effects. Finally, treatment with high-dose rimonabant
as associated with a significantly greater reduction in the
ercentage of subjects with metabolic syndrome than pla-
ebo: from 42.2% at baseline to 19.6% at one year (63) and
1.5% at two years (p 0.001 compared with placebo) (64).
HE RIO-NA TRIAL. Obese patients in North America (NA)
ere enrolled into the RIO-NA trial (65). In addition to
igure 2. Percentage of subjects achieving 10% weight loss at one year
ith rimonabant (solid bars) 20 mg/day versus placebo (open bars) in the
rst two Rimonabant in Obesity (RIO) trials among those completing the
tudy.valuating the efficacy of rimonabant for primary weight ooss, this 3,045-subject trial had evaluated whether weight
oss achieved with rimonabant could be maintained after
ithdrawal of the drug. As in prior RIO trials, subjects were
nitially randomized to rimonabant 20 mg/day, rimonabant
mg/day, or placebo for one year. However, after the
ompletion of one year of treatment, subjects in the two
imonabant groups underwent a second randomization,
ither to continue receiving their previously assigned dose of
imonabant or to be switched to a matching placebo. The
rst-year outcomes were similar to those of the other RIO
rials: weight loss was significantly greater in the rimon-
bant treatment groups (6.3 kg for 20 mg/day, 4.4 kg
or 5 mg/day vs. 1.6 kg for placebo, p  0.01 for both
omparisons). After two years, subjects re-randomized to
lacebo after the end of one year have regained much of
heir weight (overall loss of 3.2 kg vs. 2.3 kg for patients on
lacebo for two years), whereas those who were treated with
imonabant 20 mg/day for the full two years lost an average
f 7.4 kg (p  0.01 for placebo comparison). Rates of
etabolic syndrome were improved with rimonabant, with
hich a significant reduction was seen in the 20-mg dose
roup (34.8% to 21.1%) compared with placebo (31.7% to
9.2%). An increase in HDL of 24.5% was seen in the
imonabant 20 mg/day group, compared with 13.8% in the
lacebo group.
HE RIO-DIABETES TRIAL. The most recent study reported
rom the RIO phase 3 program was the RIO-Diabetes trial
66), which enrolled 1,047 patients with type 2 diabetes
ellitus and a BMI 27 to 40 kg/m2. Again, subjects were
andomized to receive rimonabant 20 mg/day, rimonabant 5
g/day, or placebo for one year. All patients were also
reated with an oral hypoglycemic drug, as prescribed by
heir treatment physician, with the majority receiving met-
ormin. At the end of one year, therapy with rimonabant 20
g was associated with an average weight loss of 5.3 kg,
ompared with 1.4 kg in the placebo group (p  0.001).
verage levels of glycosylated hemoglobin were decreased
y 0.6% in the rimonabant 20 mg group from a baseline
evel of 7.3%, but were increased in the placebo group by
.1% (p  0.001). Effects of the rimonabant 5 mg/day were
ess significant. Importantly, 43% of all subjects treated with
imonabant achieved an optimal glycosylated hemoglobin
evel of 6.5%, compared with just 21% of those receiving
lacebo (p  0.001).
In summary, the RIO trials showed that in patients
ith obesity, including those with cardiovascular comor-
idities, continued therapy with rimonabant as compared
ith placebo is associated with a significant reduction in
ody weight and waist circumference. Such therapy is
lso associated with other favorable changes in the
ardiometabolic risk profile, including an improvement in
lycemic control in type 2 diabetics, an improvement in
he lipid profile, and an overall decrease in the prevalence
f metabolic syndrome.
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Rimonabant May 16, 2006:1919–26HE STRATEGY TO REDUCE ATHEROSCLEROSIS DEVELOP-
ENT INVOLVING ADMINISTRATION OF RIMONABANT—
HE INTRAVASCULAR ULTRASOUND STUDY (STRADIVARIUS).
he ongoing STRADIVARIUS trial (67) will test whether
he improvement in the cardiometabolic risk profile effected
y rimonabant translates into changes within the coronary
irculation. The STRADIVARIUS trial is enrolling obese
ubjects who either are smokers or have at least two
dditional features that fit the standard definition of meta-
olic syndrome, and in whom a clinically indicated coronary
ngiography reveals a 20% to 50% stenosis. The volume of
theroma will be assessed by intravascular ultrasound. Sub-
ects will then be randomized to rimonabant 20 mg/day,
imonabant 5 mg/day, or placebo, and the end point will be
hange in the volume of target atheroma at the time of a
andatory repeat angiography at 18 months. There are also
lans for a large clinical outcomes trial to begin in the
oming year.
imonabant for smoking cessation: the Studies with
imonabant and Tobacco Use (STRATUS) trials. En-
olling concurrently with the RIO program, the STRATUS
rials are examining the potential role of rimonabant as an
djunct in smoking cessation (Table 5).
In a randomized, double-blind, placebo-controlled
TRATUS-United States (US) trial (68), 787 subjects were
nrolled who smoked 10 cigarettes/day (average, 23 cig-
rettes/day) for at least two months and who were motivated
o quit. Subjects were randomly assigned to receive rimon-
bant 20 mg/day, rimonabant 5 mg/day, or placebo for 10
eeks, and were asked to quit smoking on day 15 of the
tudy. End points included smoking abstinence rate as well
s a change in body weight in those who were abstinent
rom cigarettes at one year. At the end of the study, the rate
f abstinence was significantly higher in the high-dose
imonabant group compared with placebo (36.2% vs. 20.6%,
 0.001), but not in the low-dose rimonabant group
20.2%). Among subjects with prolonged abstinence, those
n the placebo group gained an average of 3.7 kg of body
eight, compared with 0.6 kg in the high-dose rimonabant
roup (p  0.001), representing an impressive 84% reduc-
ion in weight gain for rimonabant over placebo. Subgroup
nalysis showed that among subjects who were initially
verweight, those who were abstinent from tobacco while
eceiving rimonabant 20 mg/day had not gained any weight
y one year (weight change0.1 kg vs.1.7 kg for placebo,
 0.001). As with the RIO trials, no differences were
oted in the rate of dropout among the treatment groups.
The STRATUS-Europe (EU) has a protocol identical to
TRATUS-US, and is following up 789 subjects in Europe;
TRATUS-Worldwide (WW) is a large one-year mainte-
ance study with a treatment-free one-year follow-up that
as conducted among 5,055 subjects across 54 sites world-
ide. Results from both of these trials are expected within
ne year.
otential uses of rimonabant in other disorders. Involve-
ent of the endocannabinoid system in a wide variety ofeuropsychiatric, cardiac, vascular, and metabolic patho-
hysiological processes, and a wealth of animal data on both
ndogenous ligands and rimonabant, offer multiple intrigu-
ng possibilities for clinical use in humans. A phase 2 clinical
rial of rimonabant to reduce alcohol consumption is being
ponsored by the National Institutes of Health (69). Animal
xperiments showing that blockade of CB1 receptors with
imonabant attenuates shock caused by extreme hemorrhage
36), endotoxemia (38), or myocardial infarction (37) will
ikely prompt human clinical trials in the near future.
imonabant may also find use in the treatment of vasodi-
atory state and chronic hypotension in patients with ad-
anced liver disease (70).
dverse effects in clinical trials of rimonabant. Initial
xperience with rimonabant shows that it is generally well
olerated. In the RIO phase 3 program, the one-year
ropout rates were high (36% to 49%), but were typical of
besity trials and did not differ from placebo. The most
ommon adverse effect was mild nausea. Given its pharma-
ology, there is concern regarding the neuropsychiatric
ffects of rimonabant, such as higher incidence of anxiety
nd depressed mood disorders. Use of the Hospital Anxiety
nd Depression scale in RIO-Europe showed no difference
etween the treatment groups in the average subscale scores
or either major depression or anxiety (63). During one year
f treatment, six subjects (1.0%) in the rimonabant 20
g/day group and one subject (0.3%) in the placebo group
iscontinued their study drug because of depression. For
epressed mood disorders, the rates were 3.7% and 3.0% for
imonabant 20 mg/day and placebo, respectively. Similarly,
n RIO-Lipids, the Hospital Anxiety and Depression scale
cores were similar for anxiety and depression between the
wo treatment groups and placebo (62). Therefore, it seems
hat the percentage of patients experiencing neuropsychiat-
ic side effects is small. Monitoring for on-treatment anxiety
nd depression in the future will nonetheless be necessary to
nsure safe use of this important new therapy.
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